Home/Pipeline/Luvesilocin (RE104)

Luvesilocin (RE104)

Postpartum Depression (PPD)

Phase 2Active

Key Facts

Indication
Postpartum Depression (PPD)
Phase
Phase 2
Status
Active
Company

About Reunion Neuroscience

Reunion Neuroscience is a venture-backed, clinical-stage biotech company pioneering next-generation psychedelic-based mental health therapies. Its lead candidate, luvesilocin (RE104), a short-duration prodrug of a psilocybin-like compound, has received FDA Breakthrough Therapy Designation for postpartum depression following positive Phase 2 results. The company is targeting significant unmet needs in psychiatry with a pipeline focused on rapid-onset, durable antidepressant effects, leveraging a team with deep neuroscience drug development expertise.

View full company profile

About Reunion Neuroscience

Reunion Neuroscience is a venture-backed, clinical-stage biotech company pioneering next-generation psychedelic-based mental health therapies. Its lead candidate, luvesilocin (RE104), a short-duration prodrug of a psilocybin-like compound, has received FDA Breakthrough Therapy Designation for postpartum depression following positive Phase 2 results. The company is targeting significant unmet needs in psychiatry with a pipeline focused on rapid-onset, durable antidepressant effects, leveraging a team with deep neuroscience drug development expertise.

View full company profile

About Reunion Neuroscience

Reunion Neuroscience is a venture-backed, clinical-stage biotech company pioneering next-generation psychedelic-based mental health therapies. Its lead candidate, luvesilocin (RE104), a short-duration prodrug of a psilocybin-like compound, has received FDA Breakthrough Therapy Designation for postpartum depression following positive Phase 2 results. The company is targeting significant unmet needs in psychiatry with a pipeline focused on rapid-onset, durable antidepressant effects, leveraging a team with deep neuroscience drug development expertise.

View full company profile

Therapeutic Areas

Other Postpartum Depression (PPD) Drugs

DrugCompanyPhase
GH001GH ResearchPhase 2a
LPCN 1154LipocinePhase 3